IGC Pharma presents illustrative valuations for Alzheimer's treatment IGC-AD1
IGC Pharma disclosed a presentation detailing potential stock value scenarios for Alzheimer's drug IGC-AD1. The company anticipates potential valuations ranging from $300 million to $4 billion contingent upon successful clinical development and regulatory milestones.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day